Protein / target
3',5'-cyclic-AMP phosphodiesterase 4B
Protein at a glance
Biological role
3',5'-cyclic-AMP phosphodiesterase
Strongest disease association
Stroke
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
View complete UniProt function annotationHide complete annotation
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes (PubMed:15260978). May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents
Subcellular location
Domains and Gene Ontology detail (32)Hide
Domains & features
Gene Ontology
- Ccentrosome
- Ccytosol
- Cdendritic spine
- Cexcitatory synapse
- Cgamma-tubulin complex
- Cpostsynaptic density
- Csynaptic vesicle
- Cvoltage-gated calcium channel complex
- CZ disc
- F3',5'-cyclic-AMP phosphodiesterase activity
- F3',5'-cyclic-GMP phosphodiesterase activity
- Fcalcium channel regulator activity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Ion channel gating
- ·regulation of calcium ion transmembrane transport via high voltage-gated calcium channel
Cell migration
- ·neutrophil chemotaxis
Immune signalling
- ·positive regulation of interleukin-2 production
- ·T cell receptor signaling pathway
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
15 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Phosphodiesterase 4 inhibitor
Indicated for Arthritis, Psoriatic, Behcet's Syndrome, Immune System Diseases, Psoriasis
Phosphodiesterase 4 inhibitor
Indicated for Lung Diseases, Obstructive, Psoriasis, Pulmonary Disease, Chronic Obstructive
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene PDE4B
Gene-level evidence surfaced through the gene PDE4B that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
28 compounds recorded · 15 approved · 13 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (11)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis
- Indication expanded
Indication expansion: ROFLUMILAST (NDA215985)
- Indication expanded
Indication expansion: ROFLUMILAST (NDA215985)
- Indication expanded
Indication expansion: ROFLUMILAST (NDA215985)
- Regulatory approval
Approval: Apremilast Accord (EMA)
- Indication expanded
Indication expansion: ROFLUMILAST (NDA215985)
- New publicationA multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
- Safety communication
Drug Safety Update: Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour
- Safety communication
Drug Safety Update: Roflumilast (Daxas▼): risk of suicidal behaviour
- New publicationEfficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
- New publicationRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
- New publicationRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.